Company profile
BRAVEHEART BIO, INC.
NASDAQ:BRVEBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07755904 | phase3 | recruiting | 2026-09-02 | 2028-10-01 | Braveheart Bio, Inc. | BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy |
FDA applications (0)
No records yet.